Y Glatz
Overview
Explore the profile of Y Glatz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
120
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Donath M, Sutsch G, Yan X, Piva B, Brunner H, Glatz Y, et al.
J Clin Endocrinol Metab
. 1998 Sep;
83(9):3177-83.
PMID: 9745422
Insulin-like growth factor I (IGF-I) enhances myofibrillar development in cardiomyocytes of rats in culture and in vivo. In addition, IGF-I has vasodilatory effects and improves cardiac function in healthy volunteers....
2.
Bianda T, Glatz Y, Bouillon R, FROESCH E, Schmid C
J Clin Endocrinol Metab
. 1998 Jan;
83(1):81-7.
PMID: 9435420
Unlabelled: Administration of insulin-like growth factor-I (IGF-I) or growth hormone (GH) is known to stimulate bone turnover and kidney function. To investigate the effects of IGF-I and GH on markers...
3.
Bianda T, Glatz Y, FROESCH E, Schmid C
Diabetologia
. 1997 Mar;
40(3):363-4.
PMID: 9084980
No abstract available.
4.
Bianda T, Hussain M, Glatz Y, Bouillon R, FROESCH E, Schmid C
J Intern Med
. 1997 Feb;
241(2):143-50.
PMID: 9077371
Objectives: To find out whether insulin-like growth factor-I (IGF-I) mimics the stimulatory effects of growth hormone (GH) on bone turnover and renal tubular phosphate reabsorption. Design: Randomized, crossover study. Setting:...
5.
Donath M, Jenni R, Brunner H, Anrig M, Kohli S, Glatz Y, et al.
J Clin Endocrinol Metab
. 1996 Nov;
81(11):4089-94.
PMID: 8923865
To determine whether insulin-like growth factor I (IGF-I) has systemic cardiovascular effects in humans, 60 micrograms/kg IGF-I or saline were injected sc in a cross-over, randomized, double blind fashion into...
6.
Bianda T, Hussain M, Keller A, Glatz Y, Schmitz O, Christiansen J, et al.
Diabetologia
. 1996 Aug;
39(8):961-9.
PMID: 8858219
Growth hormone (GH) secretion is suppressed during insulin-like growth factor-I (IGF-I) administration. The aim of the study was to examine whether IGF-I alters the metabolic response to a GH pulse....
7.
Accuracy of devices for self-monitoring of blood glucose including hypoglycemic blood glucose levels
Zenobi P, Keller A, Glatz Y
Diabetes Care
. 1995 Apr;
18(4):587-8.
PMID: 7497881
No abstract available.
8.
Hussain M, Schmitz O, Mengel A, Glatz Y, Christiansen J, Zapf J, et al.
J Clin Invest
. 1994 Sep;
94(3):1126-33.
PMID: 8083353
Insulin-like growth factor-I (IGF-I) is considered to be the mediator of the growth-promoting effects of growth hormone (GH). The metabolic effects of these two hormones, however, are different. Whereas GH...
9.
Zenobi P, Glatz Y, Keller A, Graf S, Riesen W, Schoenle E, et al.
Eur J Endocrinol
. 1994 Sep;
131(3):251-7.
PMID: 7921209
Severe insulin resistance type A is due to mutations in the insulin receptor gene and is characterized by glucose intolerance or diabetes mellitus, despite extreme hyperinsulinemia, virilization and acanthosis nigricans....
10.
Zenobi P, Holzmann P, Glatz Y, Riesen W, FROESCH E
Diabetologia
. 1993 May;
36(5):465-9.
PMID: 8314453
Type 2 (non-insulin-dependent) diabetes mellitus is associated with increased glucose, insulin, total and VLDL-triglyceride, and often total and LDL-cholesterol levels which promote vascular disease. Recombinant human insulin-like growth factor-I which...